Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials

BackgroundThis post-hoc analysis from three phase 3 treatment trials of rimegepant 75 mg - an oral small molecule calcitonin gene-related peptide receptor antagonist for acute and preventive treatment of migraine - assessed efficacy in adults with migraine based on triptan treatment experience. MethodsParticipants were assigned to one of four groups based on triptan treatment experience: insufficient response (e.g. lack of efficacy and/or poor tolerability) to 1 triptan, insufficient response to >= 2 triptans, current triptan users, and triptan-naive participants. The co-primary efficacy endpoints were pain freedom and most bothersome symptom freedom at two hours postdose. ResultsIn the three trials (N = 3507; rimegepant n = 1749, placebo n = 1758), 1235 (35.2%) participants had a history of insufficient response to 1 triptan (n = 910 [25.9%]) or >= 2 triptans (n = 325 [9.3%]), and 2272 (64.8%) had no history of insufficient response to triptans (current use = 595 [17.0%], naive = 1677 [47.8%]). Rimegepant was effective on the co-primary endpoints in all subgroups (p <= 0.013), except for freedom from the most bothersome symptom in the triptan-naive group (p = 0.06). No differences on co-primary endpoints were found in pairwise comparisons of rimegepant-treated participants. ConclusionsRimegepant was effective for the acute treatment of migraine in adults with a history of insufficient response to 1 or >= 2 triptans and in current triptan users. Efficacy on co-primary endpoints did not differ based on the number of insufficient triptan responses.Trial registration: Clinicaltrials.gov: NCT03235479, NCT03237845, NCT03461757